BACKGROUND AND OBJECTIVES:
Myostatin (growth differentiation factor 8, has an important role in the regulation of muscle mass, and mice lacking the myostatin gene show a generalized increase in bone density and strength. Type 2 diabetes subjects have an increased risk of fragility fractures despite of higher bone mass. Taking into account the myostatin influence in bone strength a better understanding of myostatin actions in type 2 diabetes is of interest.
Our aims were to evaluate serum myostatin concentrations in type 2 diabetes patients, and to explore its relationship with bone mineral density (BMD), bone turnover markers and fractures.
DESIGN, SETTING AND PATIENTS:
Cross-sectional study including 73 patients with type 2 diabetes mellitus.
• Lumbar spine and femoral bone mineral density (BMD) were measured by dual X-Ray absorptiometry (Hologic QDR 4500). World Health Organization criteria for osteoporosis were used.
• Serum myostatin was measured using quantitative sandwich enzyme-linked immunosorbent assay (ELISA) developed by R&D systems (Minneapolis, MN, USA) according to the manufacturer's instructions. The assay sensitivity is 5,32 pg/mL and the assay range is 31,3 -2,000 pg/mL. Intra-assay and inter-assay variability were of 5.6% and 6%, respectively.
• Bone turnover markers were measured as follows: total osteocalcin by radioimmunoassay (DiaSorin, Stillwater, Minnesota USA); bone alkaline phosphatase (BSAP) by an enzyme- 
CONCLUSIONS:
1) Our data does not support an association between serum myostatin and bone parameters in type 2 diabetes. A true lack of relationship in humans may be an explanation, although a disrupted regulation of this pathway in type 2 diabetes may also take place Conflicts of interest: none.
